fbpx
Aesthetic Advancements logo

Restylane Refyne & Restylane Defyne for Treatment of Laugh Lines

As skin ages, the lines that run from the sides of your nose towards the corners of your mouth (nasolabial folds) and the lines that run from the corners of your mouth to the chin (marionette lines) become more noticeable. Patients are often looking for treatments to smooth out those lines and have natural-looking and natural-feeling results. Even with the products currently on the market, patients are always looking for different solutions.

Restylane Refyne The FDA approved Restylane Refyne and Restylane Defyne for the treatment of laugh lines in patients over the age of 21. Restylane Refyne has been approved for treating moderate to severe wrinkles and folds, and Restylane Defyne for moderate to severe deep facial wrinkles and folds. Both products are perfect complements to the rest of the Restylane line of products by Galderma.

These dermal fillers were designed using a process called XpresHAn Technology, which creates the smooth injectable gel that gives your patient’s skin natural-looking results. This technology customizes the degree of hyaluronic acid crosslinking, allowing a wide range of flexibility and support characteristics for different patients and their needs. Whereas Restylane Defyne is less flexible and designed to offer additional support, Restylane Refyne is very flexible and provides subtle support.

The reason these next generation dermal fillers are getting attention is because of their natural-looking results. They have been shown to help maintain natural expressions and movements. Results can last up to 12 months after injection and have the same injection site response (redness, bruising, lump/bump formation, swelling, pain, tenderness etc) as similar Restylane products.

If you are looking for a dermal filler treatment to offer your patients who are looking to smooth out their laugh lines, you may want to check out Restylane Defyne and Refyne. Make sure to do your research before injecting.